. 2022 Nov 11;20:477. doi: 10.1186/s12951-022-01677-2

Table 2.

Summary of significantly upregulated immune cells phenotypes

Immune cell phenotypes	ID Vaccination	IM Vaccination
Activated myeloid cells in TBLN MNCs [CD3⁻CD172⁺CXCL10⁺]	**p < 0.01
IFNγ⁺ Effector memory T-helper/Memory cells in PBMCs [CD3⁺CD4⁺CD8α⁺CD8β⁻CD27⁻IFNγ⁺]	*p < 0.05
Total IL-17A⁺ T-helper/Memory cells in PBMCs [CD3⁺CD4⁺CD8α⁺CD8β⁻IL-17A⁺]	**p < 0.01
IL-17A⁺ Central memory T-helper/Memory Cells in PBMCs [CD3⁺CD4⁺CD8α⁺CD8β⁻CD27⁺IL-17A⁺]	**p < 0.01
IL-17A⁺ Effector memory T-helper/Memory cells in PBMCs [CD3⁺CD4⁺CD8α⁺CD8β⁻CD27⁻IL-17A⁺]	**p < 0.01
Total IL-17A⁺ CTLs in PBMCs [CD3⁺CD4⁻CD8α⁺CD8β⁺IL-17A⁺]	^♯p < 0.05
IL-17A⁺ Early effector CTLs in PBMCs [CD3⁺CD4⁻CD8α⁺CD8β⁺CD27⁺IL-17A⁺]	^♯p < 0.05
Total IL-17A⁺ CTLs in TBLN MNCs [CD3⁺CD4⁻CD8α⁺CD8β⁺IL-17A⁺]		^##***p < 0.01
IL-17A⁺ Late effector CTLs in PBMCs [CD3⁺CD4⁻CD8α⁺CD8β⁺CD27⁻IL-17A⁺]		***p < 0.001

Only significantly enhanced immune cell subsets in NanoS100-SwIAV vaccinates compared to their non-adjuvanted counterparts in either ID or IM vaccinated SPF pigs at DPC6 were presented

Asterisk represents significant difference between indicated groups (*/♯ p < 0.05, **/♯♯ p< 0.01, and ***/♯♯♯ p < 0.001)